mydrugindex
Kenyan Reference & Directory
Free lookups today: 2/3 · Unlimited with Pro Subscribe from KES 99
Free lookups: 2/3 Unlimited with Pro → Browse by class Interactions · Tip: type at least 2 letters, then pick a result

INN monograph

Methyldopa

Therapeutic agent (verify pharmacological class) · POM

POM

Verified · Updated 01 Aug 2026 · Source: Local active-ingredient clinical extract; RxNorm (NLM RxNav); PubChem; Professional class pharmacology (Therapeutic agent (verify pharmacological class))

Class
Therapeutic agent (verify pharmacolo...
Schedule
POM
Route
See product SmPC
Onset
Product-specific
Duration
Product-specific
Pregnancy
Use only if potential be...
Renal
Review renal impairment...
High-alert
No

Kenya market

Wholesale / list prices where loaded

From
KES 600
Median
KES 600
Brands
9

Risk first

Contraindications

  • Hypersensitivity to the active substance or excipients.
  • Additional absolute contraindications are indication- and product-specific — consult SmPC.

Precautions

  • Obtain allergy and medication history.
  • Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs.
  • Use the lowest effective dose for the shortest appropriate duration.
  • Monitor for expected class adverse effects.

Point of care

Dosing

Adult

Starting dose: 250mg BD or TID x 2/7 adjust until the desired effect is achieved. Max. 3g daily. Children 10mg/kg daily in 2-4 doses [max. 65mg/kg or 3g daily whichever is less]. To minimize sedation, start dosage increases in the evening. When methyldopa tablets are added to a thiazide, the dosage of thiazide need not be changed. When methyldopa is given with other antihypertensives apart from thiazides for initial therapy the dosage of methyldopa should not exceed 500mg daily. After withdrawal of methyldopa, hypertension returns after 48 hours.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.

Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

Safety

Drug interactions

Open checker →
  • Professional use: confirm indication, dose, duration, monitoring and patient counselling points against current Kenya STG / EML and the product SmPC.
  • Document allergy status and key interactions.

Safety

Adverse effects

  • Peripheral oedema
  • drug fever
  • mental depression
  • nightmares
  • unusually vivid dreams
  • hepatic disorders
  • auto-immune haemolytic anaemia
  • reversible leukopaenia
  • reversible granulocytopenia
  • myocarditis
  • pancreatitis
  • systemic lupus erythematosus [SLE]-like syndrome
  • thrombocytopenia
  • drowsiness

Use

Indications

  • Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)).
  • Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
  • Hypertension

Pharmacology

Mode of action

Centrally acting antihypertensive.

Centrally acting antihypertensive. The major antihypertensive effect appears… Stimulation of alpha-2 adrenergic receptor…
Full mechanism text

Centrally acting antihypertensive. The major antihypertensive effect appears to be due to its conversion to alpha-methyl-norepinephrine, which is a potent alpha-2 adrenergic agonist. Stimulation of alpha-2 adrenergic receptors results in a decrease in sympathetic outflow and decreased blood pressure.

ADME

Pharmacokinetics & PD

Onset Product-specific
Duration Product-specific
Route See product SmPC
Elimination are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
Half-life when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Full PK/PD text

Absorption, distribution, metabolism and excretion are product-specific. Consider food effects, protein binding, hepatic CYP/UGT metabolism, renal clearance and half-life when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.

Kenya

Brands & prices

9 listed
Brand Company Pack KES
Aldomet Aspen Pharmacare Standard Commercial Pack
Biodopa Biodeal Laboratories Ltd. Standard Commercial Pack
Dawadopa Dawa Limited Standard Commercial Pack
Dopamac Macleods Pharmaceuticals Ltd. Standard Commercial Pack
Hydopa Laboratory & Allied Ltd. Standard Commercial Pack
M Dopa Prism Life Sciences Standard Commercial Pack
Medopasel Distributed by Medisel (K) Limited Standard Commercial Pack
Medopress Cosmos Limited. Standard Commercial Pack
Methyldopa Global Napi Pharmaceuticals Standard Commercial Pack 600.00

Special populations

Pregnancy & lactation

Pregnancy

Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

Diet

Food & alcohol

  • Food
  • Food

Trust

Sources & disclaimer

Source: Local active-ingredient clinical extract; RxNorm (NLM RxNav); PubChem; Professional class pharmacology (Therapeutic agent (verify pharmacological class))

Open source link

Last reviewed: 01 Aug 2026

Decision support only — not a substitute for clinical judgment, product SmPC, or Kenya STG/EML.

Kenya Verified Health Registry